Introduction
Atrial natriuretic factor (ANF),' a polypeptide hormone released by atrial myocytes (for reviews see references 1 and 2), causes sodium and water diuresis (3, 4) , vascular smooth muscle relaxation (5, 6) , and-inhibition of renin (7) and aldosterone §cretion (8) (9) (10) . Although many of its physiologic effects are recognized, much remains to be lfarned about ANF at a molecular level.
Cyclic guanosine monophosphate (cGMP) may be an important mediator of ANF action. Atrial extracts injected into rats ipcreased plasma and urine levels of cGMP; the latter increase was thought to result from renal production (11) . ANF increased cGMP levels in isolated kidney cells (12) , renal glomeruli and other defined nephron segments (13) (14) (15) , and cultured vascular smooth muscle preparations (16) . In vascular smooth muscle preparations, ANF-induced increases were correlated with an apparently endotheium-independent vasorelaxation (17) . ANF stimulation of particulate guanylate cyclase has been demonstrated in numerous tissues, including rat aorta, kidney, lung, liver, intestine, and testes (18) . Based on a 20,000-fold copurification of ANF binding and guanylate cyclase activity from rat lung, at least one type of ANF-receptor apparently has intrinsic guanylate cyclase activity (19).
Modulation of cellular cAMP levels may be another mechanism of ANF action. ANF receptor-mediated inhibition of adenylate cyclas6 activity has been described in pituitary and adrenal cortical membranes and in homogenates of aorta and rat mesenteric and renal arteries (20) (21) (22) . Reduced cAMP content has been reported to accompany elevated cGMP content in response to ANF treatment of isolated rat renal papillary cells (12) . Reported effects of ANF on kidney membrane adenylate cyclase, however, have been mixed. No effect was seen with rat kidney membranes (18) . In dog, ANF inhibited membrane adenylate cyclase activity of glomeruli, loops of Henle, and collecting ducts, but not proximal tubules (23) . cAMP levels of aortic strips were unaffected by ANF treatment, even though ANF causes relaxation of the tissue ( 17) .
One system in which receptor regulation of cyclic nucleotide levels has been well characterized is the human skin fibroblast. Adenylate cyclase activation and inhibition and guanylate cyclase activation have all been demonstrated in these cells (24) (25) (26) . We now report in human skin fibroblasts a novel mechanism of ANF action: reduction of cAMP content through activation of a phosphodiesterase rather than inhibition of adenylate cyclase. Binding of ANF to 3-10 jig cell membranes was assayed using 50 pM '25I-ANF(Ser 99-Tyr 126 ANF) (25,000 cpm/tube) with different concentrations of ANF(Ser 99-Tyr 126 ANF) in 50 mM Tris-HCI, pH 7.5/0.1% BSA/0.1% bacitracin, containing-0.25 ,g each of pepstatin, leupeptin, soybean trypsin inhibitor, and chymotrypsin inhibitor (total volume, 0.25 ml): After incubation for 30 min at 30°C, samples were filtered according to Bruns et al. (27) . Binding parameters were fitted with the LIGAND nonlinear least squares of curve-fitting program (28) . Nonspecific binding was < 10% of total.
Miscellaneous. Protein was assayed according to Lowry et al. (29) using BSA as the standard for binding assays. For cAMP and cGMP determinations, protein was assayed with a dye-binding kit (Bio-Rad Laboratories, Richmond, CA) using gamma globulin as standard. Significance was determined by analysis of variance using paired t testing. Significance is defined as P < 0.05.
Results
Over the range of concentrations assayed, ANF(Ser 99-Tyr 126) apparently bound to a single class of high affinity sites in human fibroblast membranes (Kd = 66±18 pM; maximum number of binding sites [Bmax] = 1,205±217 fmol/mg protein or 7,000 sites/cell) (data not shown).
Basal cAMP content of fibroblasts was unaffected by 1 uM ANF,-whereas cAMP accumulation stimulated by isoproterenol or PGE, was significantly decreased (Table I ). The inhibitory effect of ANF was concentration-dependent, with a 50% inhibitory concentration (IC50) of 1I0-1Q M (Fig. 1 ). Some degree of inhibition occurred at all concentrations of isoproterenol ( Fig. 2 A) and at PGEI concentrations > 0.03 gg/ml (Fig. 2 B) . ANF inhibition was dependent on time of incubation. Maximal percentage inhibition with isoproterenol was observed at 10 min and with PGE1 at 5-10 min (data not shown).
Incubation of cells with pertussis toxin, which blocks the function of Gi (30) , the guanyl nucleotide-binding protein that couples inhibitory receptors to adenylate cyclase (31), decreased basal cAMP content and cAMP accumulation in response to isoproterenol and PGE,, but did not interfere with the inhibitory effect of ANF (Table II) . Toxin treatment, however, abolished the inhibitory effect on both PGE,-and isoproterenol-stimulated cAMP of carbamylcholine, which acts through Gi to inhibit adenylate cyclase (Table III) ; thus, in this system, Gi was not involved in ANF action.
Incubation of fibroblasts with the phosphodiesterase inhibitor IBMX (l0-I M) elevated basal and isoproterenol-and PGEI-stimulated cAMP content (Table I ). In the presence of (Table IV) . Isoproterenol-and PGE1-stimulated cAMP contents were enhanced; the inhibitory effect of ANF was substantially reduced. Cilostamide, another selective cAMP phosphodiesterase inhibitor, had relatively little effect on basal, isoproterenol-, or PGEI-stimulated cAMP (Table IV) . There was, however, marked attenuation of the ANF-dependent inhibition of agonist-stimulated cAMP (Table IV) . MB 22948, a somewhat selective inhibitor of cGMP phosphodiesterases, did not block the ANF response in an experiment in which IBMX inhibited the response (Table V) . MB 22948 at the concentration used in this experiment (1 uM) significantly enhanced ANF-stimulated cGMP, with minimal effects on PGE1-stimulated cAMP. At 10 ,uM, stimulatory effects on agonist-enhanced cAMP and cGMP were observed (data not shown). No difference in cAMP or cGMP phosphodiesterase activity was observed in supernatant and particulate fractions prepared from control and ANF-treated fibroblasts 0.8* (3) Experiments (in quadruplicate) were performed as described in Table  II M; cGMP content was still rising at 10-5 M ANF (the maximal concentration tested) (Fig. 3) . There was no apparent effect of pertussis toxin upon the cGMP response to ANF (data not shown). The effect of ANF on cGMP content was time dependent (Fig. 4) , with a rapid rise and fall within 2 min. IBMX exaggerated and prolonged the ANF effect. Untreated cells or those treated with IBMX alone did not exhibit any significant changes in cGMP. 
Discussion
ANF reduced cAMP content in isoproterenol-or PGEI-treated but not in untreated fibroblasts. As in other systems, ANF treatment increased cellular cGMP content in a dose-dependent manner. Although our findings are consistent with a single class of ANF receptors on fibroblast membranes, from the 1,000-fold difference in the potency of ANF to reduce cAMP content (IC50 = 100 pM) and elevate cGMP content (EC50 > 100 nM), one may infer that a second class ofANF receptors went undetected in the binding studies. Based on its affinity (Kd = 66 pM), the site we describe is presumably the one that mediates the effect of ANF on fibroblast cAMP levels. The very low potency of ANF to stimulate guanylate cyclase in Atrial Natriuretic Factor Activation ofFibroblast Phosphodiesterase ment, which ADP-ribosylated all available Gi and blocked muscarinic inhibition of adenylate cyclase, did not block ANF effects on cellular cAMP content. We conclude that the mechanism of ANF action in fibroblasts, unlike other tissues that have been studied, is to increase cAMP degradation rather than to inhibit its synthesis. The fact that 8-bromo cGMP inhibited the effects of ANF on isoproterenol-stimulated cAMP supports a role for the nucleotide as a possible intermediate. The possibilities for its action are diverse, including activation of a cAMP phosphodiesterase or cGMP-dependent protein kinase (33, 34) . It is possible, however, that exogenous 8-bromo cGMP may elicit a response different from that found with endogenous cGMP. Further study of this pathway is clearly necessary. Although the ANF and muscarinic mechanisms differ in the fibroblasts, muscarinic receptor modulation of cellular cAMP levels in another cell type may provide a model for ANF action in fibroblasts. In addition to the Gi-mediated muscarinic inhibition of adenylate cyclase that occurs in the fibroblasts and in NG108-15 neuroblastoma X glioma hybrid cells (35), muscarinic activation of a phosphodiesterase without inhibition of adenylate cyclase has been reported in the 132 lNl astrocytoma cell line. Like ANF in the fibroblasts, carbamylcholine had no effect on basal cAMP levels in the astrocytoma cells but reduced PGEI-and isoproterenol-stimulated levels in a manner that was blocked by IBMX and not by pertussis toxin (36) (37) (38) . That the carbamylcholine effect in the astrocytoma is a calcium-dependent phenomenon (37, 38) raises the possibility of a similar mechanism for ANF activation of a phosphodiesterase in the fibroblasts.
